In this report we demonstrate that the transgenic expression of VILIP-1 targeted to the epidermis is able to decrease the baseline levels of cell proliferation and that this downregulation of epidermal proliferation is also very evident after short term treatment with the hyperplasiogenic tumor promoter TPA. Here, VSNL1 is linked to neoplasm.